COMMUNIQUÉS West-GlobeNewswire

Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium

03/09/2024 - 13:00

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the Study of Inborn Errors of [...]

CMR Surgical Strengthens Senior Team

03/09/2024 - 13:00

CMR Surgical Strengthens Senior Team Markus Bauman, seasoned senior executive has been appointed Chief Legal & Business Affairs Officer and will join CMR’s executive leadership team Michelle Paknad, appointed Senior [...]

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

03/09/2024 - 13:00

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced [...]

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

03/09/2024 - 13:00

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue ™ protein degraders into the [...]

BVI to Launch New SERENITY and SERENITY Toric Premium Monofocal IOLs, Delivering an Extended Range of Vision to More Patients, at the 2024 ESCRS

03/09/2024 - 12:45

Non-diffractive IOLs SERENITY and SERENITY Toric are the second generation of BVI’s original, innovative ISOPURE premium monofocal IOL launched in 2019. These IOLs incorporate patented ISOFOCAL optic technology to [...]

Dyne Therapeutics Announces Key Leadership Appointments

03/09/2024 - 12:31

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs - WALTHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: [...]

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)

03/09/2024 - 10:00

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X receptor (FXR) agonist [...]

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio

03/09/2024 - 09:00

INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. [...]

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

03/09/2024 - 09:00

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue ™ protein degraders into the [...]

QIAGEN N.V. launches non-US offering of net share settled convertible bonds

03/09/2024 - 08:36

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]

New European Customer Orders Nexstim NBS System 5

03/09/2024 - 08:00

Press release, Helsinki, 3 September 2024 at 9 AM (EEST) New European Customer Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new European [...]

CMR Surgical Strengthens Senior Team

03/09/2024 - 08:00

CMR Surgical Strengthens Senior Team Markus Bauman, seasoned senior executive has been appointed Chief Legal & Business Affairs Officer and will join CMR’s executive leadership team Michelle Paknad, appointed Senior [...]

ONWARD® Medical and Partners Awarded Christopher & Dana Reeve Foundation Grant to Further Study Brain-Computer Interface System

03/09/2024 - 07:30

Grant will enable ONWARD Medical, CEA-Clinatec and .NeuroRestore to evaluate the use of the ONWARD ARC-BCI™ System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI) EINDHOVEN, the [...]

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

03/09/2024 - 07:00

VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populations Significant anamnestic antibody response observed across all six serotypes, [...]

Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 après une vaccination de rappel pour le candidat vaccin contre la maladie de Lyme

03/09/2024 - 07:00

Forte réponse immunitaire démontrée dans les populations pédiatriques et adultes un mois après une vaccination avec une deuxième dose de rappel (31 ème mois) dans l’étude VLA15-221 Forte réponse anamnestique observée [...]

CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive Committee member to develop CARBIOS’ presence with brands worldwide

03/09/2024 - 06:45

Clermont-Ferrand (France), 3 September 2024 (06:45 CET). CARBIOS , (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and [...]

Tommy Maussin rejoint le comité Exécutif de CARBIOS en tant que Directeur Marketing pour développer mondialement la présence de CARBIOS auprès des marques

03/09/2024 - 06:45

Clermont-Ferrand (France), le mardi 3 septembre 2024 (06h45 CEST) : CARBIOS (Euronext Growth Paris : ALCRB), pionnière dans le développement et l'industrialisation de technologies biologiques pour réinventer le cycle de [...]

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

03/09/2024 - 00:40

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

02/09/2024 - 23:00

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central [...]